⨯

  • 19 Jan 21

ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy

ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy

ReNeuron Group plc | RENE | 4.0 0 0%

    • 254 views

 

ReNeuron Group PLC's (LON:RENE) Michael Hunt talks to Proactive London following news on their data from their latest clinical assessment, which will be presented later this year. 

Hunt talks through the phase IIa extension study of its human retinal progenitor cell therapy for degenerative eye disease.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via the share buttons below. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

ReNeuron (LON:RENE) Presenting at the Proactive One2One Virtual Forum 25th February 2021

Companies: ReNeuron Group plc

ReNeuron's retinal treatment 'appears to have sustained long-term beneficial effect'

Companies: ReNeuron Group plc

ReNeuron – Edison Open House interview

Companies: ReNeuron Group plc

ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating Huntington's disease

Companies: ReNeuron Group plc

ReNeuron Group PLC: Proactive One2One Virtual Conference

Companies: ReNeuron Group plc

ReNeuron looking at applications of its own technology to deliver virus vaccine

Companies: ReNeuron Group plc

Copyright © 2023 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top